|Description||CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It inhibits the growth of castration-resistant prostate cancer cells. It offers a novel therapeutic approach against major types of castration-resistant prostate cancers.|
|Solubility||10 mM in DMSO|
|Application||CH5137291 offers a novel therapeutic approach against major types of castration-resistant prostate cancers.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||654.4±65.0 °C | Condition: Press: 760 Torr|
|Density||1.65±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM.
AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...
Pyrvinium pamoate, a nonabsorbed anthelmintic drug, is a potent androgen receptor inhibitor and a selective WNT pathway inhibitor. Pyrvinium pamoate is a potent...
ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...
CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It ...
RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-depe...
LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...
ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate canc...
RD 162 is an orally bioactive and second-generation antagonist of androgen receptor (AR). It inhibits 18F-FDHT binding to AR in human prostate cancer cells thus...
BMS-564929 is a novel androgen receptor (AR) modulator (Ki= 2.11 nM) which has been advanced to clinical trials for the treatment of age-related functional decl...
MK-0773 is a selective androgen receptor modulator for the prevention and treatment of muscle wasting associated with cancer. It designed to improve muscle func...
GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phas...
N-desmethyl Enzalutamide is a major metabolite of Enzalutamide. Enzalutamide is an androgen-receptor (AR) antagonist (IC50 = 36 nM) in LNCaP cells that inhibits...
MK-3984 is a androgen receptor modulators. It can be used for the prevention and treatment of muscle wasting associated with cancer.
ARN-509, also known as JNJ-56021927, is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby p...
MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...
Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs.
Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer...
GLPG0492, a selective androgen receptor modulator, could be effective in decreasing muscle loss. The treatment study against Duchenne muscular dystrophy of it h...
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.